| Literature DB >> 25327979 |
Laura S van Dam1, Verena M de Zwart1, Friederike A G Meyer-Wentrup1.
Abstract
Programmed cell death-1 (PD-1) and its ligands, PD-L1 and PD-L2 maintain self-tolerance and modulate physiological immune responses. Recently, targeting the PD-1/PD-L1 pathway with blocking antibodies has emerged as a potentially promising approach to treat advanced cancers in adult patients. Since tumor PD-L1 expression is currently considered the most important predictive biomarker for successful checkpoint blockade, we summarize expression data for the most common tumors of childhood. Additionally, we give an introduction into PD-1 function in the immune system to then focus on PD-1 mediated tumor immune escape. Pediatr Blood Cancer 2015;62:190-197.Entities:
Keywords: PD-1/PD-L1; cancer immunotherapy; immune checkpoint blockade; pediatric cancer
Mesh:
Substances:
Year: 2014 PMID: 25327979 DOI: 10.1002/pbc.25284
Source DB: PubMed Journal: Pediatr Blood Cancer ISSN: 1545-5009 Impact factor: 3.167